S1057 A Randomized Phase I Study Comparing Pharmacokinetics, Safety and Immunogenicity of High Concentration Formulation (100 mg/mL) With GP2017 Formulation (50 mg/mL), an Adalimumab Biosimilar, in Healthy Male Subjects - Rondon, Juan Carlos; Von Richter, Oliver; Fey, Constanze; Fan, Jamie; Furlan, Fabricio; Lemke, Lena (The American journal of gastroenterology, 2022)
Keywords: Biological products; Gastroenterology; Monoclonal antibodies; Pharmacokinetics; TNF inhibitors